Eflornithine is one molecule with three very different jobs. As Vaniqa cream, it slows the growth of unwanted facial hair in women. As Iwilfin tablets, approved in December 2023, it reduces the risk of relapse in children and adults with high-risk neuroblastoma. And as an intravenous medicine, it has been used for decades against African sleeping sickness, usually today in a combination with nifurtimox. All three uses come from the same action: eflornithine blocks an enzyme called ornithine decarboxylase, which cells need to grow and divide.
This guide covers each use in turn: how Vaniqa works and what to expect (it is not a hair remover), how to apply it and what side effects to watch for, how Iwilfin fits into neuroblastoma treatment, how eflornithine is used against sleeping sickness, and answers to the most common questions. It also replaces our separate page on Vaniqa cream.
This is general information based on FDA labeling, FDA announcements, and public health guidance, not medical advice. Excess facial hair, cancer treatment, and sleeping sickness all need proper evaluation by a healthcare professional.
Eflornithine at a glance
| Product | What it is | Approved use |
|---|---|---|
| Vaniqa | 13.9% cream applied to the skin | Reduction of unwanted facial hair in women |
| Iwilfin | 192 mg oral tablets | Reduce risk of relapse in adults and children with high-risk neuroblastoma who responded to prior therapy (approved December 13, 2023) |
| Intravenous eflornithine | Infusion given in a treatment center | African sleeping sickness caused by T. b. gambiense (usually with nifurtimox) |
How eflornithine works
Eflornithine (also called DFMO) inhibits ornithine decarboxylase, an enzyme that makes polyamines, small molecules that dividing cells rely on. Cutting off polyamine production slows cell division and some cell functions.
- In hair follicles, the Vaniqa label explains that animal data indicate inhibition of ornithine decarboxylase inhibits cell division and synthetic functions that affect the rate of hair growth, and that the cream has been shown to retard the rate of hair growth in non-clinical and clinical studies.
- In neuroblastoma, the same enzyme is part of a cancer-driving pathway, and blocking it after treatment can help prevent regrowth.
- In sleeping sickness, the parasite depends on this enzyme to multiply.
That shared mechanism explains why one drug works in such different situations, and why the dose and route matter so much: a cream applied to the face delivers very little into the bloodstream, while tablets and infusions deliver a lot.
Part 1: Vaniqa cream for unwanted facial hair
What Vaniqa is approved for
Vaniqa (eflornithine hydrochloride) Cream, 13.9% is indicated for the reduction of unwanted facial hair in women. It has been studied on the face and adjacent areas under the chin. It is a prescription medicine.
Excess facial hair can have many causes, from normal variation and genetics to hormonal conditions such as polycystic ovary syndrome. Vaniqa treats the appearance and does not treat an underlying cause. If facial or body hair has increased quickly, comes with irregular periods, acne, or a deepening voice, see a doctor to find out why.
It is not a hair remover
This point trips people up. The label says the medication is not a depilatory. It appears to retard hair growth, which improves the condition and appearance. Patients will likely need to continue using a hair removal method, such as shaving or plucking, alongside it. Vaniqa does not remove existing hair and does not stop hair follicles permanently.
How to use it
From the label and patient leaflet:
- Apply a thin layer to the affected areas of the face and adjacent areas under the chin, and rub it in thoroughly.
- Use twice a day, at least 8 hours apart, or as directed by your doctor.
- Do not wash the treated area for at least 4 hours after applying.
- Wash your hands after applying.
- Cosmetics and sunscreen can be used after a few minutes, once the cream has been absorbed. (The UK leaflet for the 11.5% product advises waiting at least 5 minutes.)
- Avoid your eyes, nose, and mouth. If the cream gets in your eyes, rinse thoroughly with water and contact your doctor.
- It is for external use only, on the skin of the face. It is not for use in the eyes, mouth, or vagina.
- If you miss a dose, do not “make it up.” Return to your normal schedule.
- Do not use it if you are under 12, according to the patient information.
- Store at 15°C to 30°C (59°F to 86°F). Do not freeze.
What to expect and when
- Improvement can begin in as little as 4 to 8 weeks, based on the 24-week clinical trials described in the label. Many people need longer.
- It works while you use it. The condition may return to pretreatment levels about 8 weeks after you stop.
- Continue other hair removal in the meantime.
- If there is no improvement after about 4 months, talk to your doctor, as the UK leaflet advises.
Side effects
Most side effects are skin reactions at the application site. Adverse events were primarily mild and generally resolved without medical treatment or discontinuation, and only 2% of participants stopped treatment in studies because of an adverse event related to Vaniqa.
- Common: acne, redness, stinging, burning, or tingling, and a rash. The label says pseudofolliculitis barbae (bumps from ingrown hairs), folliculitis (hair bumps), and dry skin can occur, and the UK leaflet lists acne as very common and dry skin, hair loss, and inflammation around the hair shaft as common.
- Less common: contact dermatitis, swelling of the lips, cheilitis (cracked lips), rosacea, numbness, and bleeding skin.
- Broken skin stings more. The label notes transient stinging or burning may occur when applied to abraded or broken skin, so avoid it on cuts and just after shaving if that bothers you.
- If irritation develops, the label advises temporarily reducing the frequency (for example to once a day). If it continues, stop using it.
- Stop and get help for signs of an allergic reaction such as hives, swelling of the face, or trouble breathing. The cream is contraindicated in anyone with a history of sensitivity to any of its components.
Laboratory abnormalities have not been consistently associated with Vaniqa, though in one open-label study some patients showed an increase in liver enzymes, and the clinical significance is not known.
Absorption, pregnancy, and safety
Very little of the cream enters the body. At steady state, the label estimates the peak concentration and daily exposure are approximately 100-fold and 60-fold lower, respectively, than with a 370 mg oral dose taken once daily. Eflornithine is not known to be metabolized and is primarily excreted unchanged in the urine.
- Pregnancy. No clinical studies have been performed in pregnant women. Animal studies showed problems only at very high doses, mainly when the animals licked or ingested the product, and the label rates it Pregnancy Category C. If you are pregnant or plan to be, ask your doctor whether to use it, and the UK leaflet advises against using it in pregnancy or breastfeeding.
- Breastfeeding. Ask your doctor.
- Overdose. A 30 g tube contains 4.2 g of eflornithine hydrochloride. Swallowing or using very large amounts should prompt medical monitoring. Keep it out of the reach of children.
Other options for unwanted facial hair
Vaniqa is one tool. Others include shaving, waxing, threading, depilatory creams, laser hair removal, electrolysis, and, when a hormonal cause is found, treating that cause with a doctor. For skin irritation after any hair removal, gentle skin care and daily sunscreen help. See our guide to anti-aging skin care for sensible, evidence-based basics, and our Fitzpatrick skin type quiz if you are considering light-based hair removal, since skin type affects risk.
Part 2: Iwilfin (eflornithine tablets) for neuroblastoma
What neuroblastoma is
Neuroblastoma is a cancer of immature nerve cells, mostly affecting infants and young children. High-risk neuroblastoma is among the hardest childhood cancers to cure, and it often relapses after intense treatment that can include chemotherapy, surgery, stem cell transplant, radiation, and immunotherapy against a target called GD2.
What the FDA approved
On December 13, 2023, the FDA approved eflornithine (Iwilfin, from USWM) to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma who have demonstrated at least a partial response to prior multiagent, multimodality therapy that included anti-GD2 immunotherapy. The FDA described it as the first approval of a therapy intended to reduce the risk of relapse in pediatric patients with high-risk neuroblastoma. It is an oral maintenance therapy, taken as 192 mg tablets.
What the evidence showed
Approval was based on a multi-site, single-arm study compared with an external control group. In the FDA summary, 105 eligible patients received eflornithine orally twice daily at a dose based on body surface area until disease progression, unacceptable toxicity, or for a maximum of 2 years. The company’s announcement reported that four years after immunotherapy, event-free survival was 84% in the treated group compared with 73% in the external control group, and that overall survival also improved.
An important caveat: this was not a randomized trial. Comparisons with external controls are less certain than randomized trials, which is why doctors interpret the results cautiously while welcoming a new option in a disease with limited choices.
Who prescribes it
Iwilfin is prescribed by pediatric oncologists as part of a treatment plan after other therapy. Dosing is based on body surface area and monitored by the care team, with regular blood tests and check-ups. Families should ask the oncology team about side effects, monitoring, and what to report.
If your child has neuroblastoma, the most useful guide is your child’s oncology team. National organizations for childhood cancer can also point to support and clinical trials.
Part 3: Eflornithine for sleeping sickness
African trypanosomiasis (sleeping sickness) is caused by Trypanosoma brucei parasites spread by tsetse flies. In its second stage, when parasites reach the central nervous system, the illness causes confusion, sleep disturbance, and eventually coma if untreated.
According to the CDC’s clinical guidance, second-stage infection with T. b. gambiense is treated with nifurtimox-eflornithine combination therapy (NECT) or fexinidazole, depending on severity and available regimens. The CDC notes NECT appears to be more effective and less toxic than eflornithine alone. It also states that eflornithine is not effective against T. b. rhodesiense and is not recommended for that form.
- How it is given. NECT combines 14 intravenous eflornithine infusions over 7 days with oral nifurtimox taken three times a day, according to the Drugs for Neglected Diseases initiative (DNDi), which helped develop the regimen.
- Side effects. The CDC lists fever, itching, high blood pressure, nausea, vomiting, diarrhea, abdominal pain, headaches, myelosuppression (reduced blood cell production), and, more rarely, seizures.
- History. The intravenous form was approved by the FDA in 1990 for this illness. The Vaniqa label notes that high-dose intravenous use (about 400 mg/kg/day) has been associated with hair loss, facial swelling, seizures, hearing impairment, stomach upset, loss of appetite, headache, weakness, and dizziness, and with blood-cell problems that were usually reversible after stopping.
Sleeping sickness treatment is provided in specialized programs in affected countries, often with support from public health organizations. See our guide to nifurtimox and Lampit for the other half of the combination.
Comparing the three uses
| Vaniqa | Iwilfin | Intravenous (NECT) | |
|---|---|---|---|
| Route | Cream on the face | Tablets by mouth | Infusion in hospital or clinic |
| Amount reaching the body | Very small | Systemic | Systemic, high |
| Typical duration | Ongoing while wanted | Up to 2 years | About 7 days (with nifurtimox for 10 days) |
| Who uses it | Women with unwanted facial hair | Patients with high-risk neuroblastoma | Patients with second-stage T. b. gambiense infection |
| Main side effects | Local skin irritation, acne | Determined by oncology team | Fever, blood, blood pressure, GI effects, seizures |
Questions to ask your healthcare provider
For Vaniqa:
- Could a medical condition be causing my facial hair?
- How long should I try it before deciding if it works?
- How should I handle irritation?
- Is it safe with my other skin products, and should I avoid it if I might be pregnant?
For Iwilfin:
- How does it fit into my child’s treatment plan?
- What monitoring, blood tests, and side effects should we expect?
- How long will treatment last, and what happens if it stops working?
For sleeping sickness:
- Which regimen is available and appropriate for this stage?
- How will side effects such as seizures and blood changes be monitored?
Frequently asked questions
What is eflornithine used for?
It has three main uses: as Vaniqa cream to reduce unwanted facial hair in women, as Iwilfin tablets to reduce relapse risk in high-risk neuroblastoma, and intravenously for African sleeping sickness.
Does Vaniqa remove hair?
No. It slows the rate of hair growth. The label says it is not a depilatory, and users will likely need to keep shaving, plucking, or using another method.
How long does Vaniqa take to work?
Improvement was seen after as little as 4 to 8 weeks in 24-week trials. The condition may return to pretreatment levels about 8 weeks after stopping.
What are Vaniqa’s side effects?
Mostly mild skin reactions: acne, redness, stinging or burning, rash, dry skin, and ingrown hair bumps. If irritation develops, reduce to once a day and stop if it continues.
Can I use Vaniqa while pregnant?
No clinical studies were performed in pregnant women. Discuss it with your doctor, and the UK leaflet advises against use in pregnancy and breastfeeding.
What is Iwilfin?
The brand name of eflornithine 192 mg tablets, FDA-approved in December 2023 to reduce the risk of relapse in patients with high-risk neuroblastoma who responded to prior therapy including anti-GD2 immunotherapy.
Is eflornithine used for sleeping sickness today?
Yes, mainly as part of nifurtimox-eflornithine combination therapy (NECT) for second-stage T. b. gambiense infection, or with alternatives such as fexinidazole depending on the situation.
Is eflornithine the same as DFMO?
Yes. DFMO (difluoromethylornithine) is another name for eflornithine.
Does topical eflornithine affect the whole body?
Very little enters the bloodstream. The label estimates peak levels and daily exposure are far lower than with an oral dose.
References
- DailyMed. VANIQA (eflornithine hydrochloride) cream, 13.9%: label.
- Vaniqa 11.5% cream: patient information leaflet (UK).
- FDA. FDA approves eflornithine for adult and pediatric patients with high-risk neuroblastoma (December 2023).
- Duke ES, et al. FDA approval summary: eflornithine for high-risk neuroblastoma after prior multiagent, multimodality therapy (PMC, 2024).
- US WorldMeds. Announcement of FDA approval of IWILFIN (eflornithine), December 2023.
- CDC. Clinical care of human African trypanosomiasis (sleeping sickness).
- DNDi. Nifurtimox-eflornithine combination therapy (NECT).
- MedlinePlus. Eflornithine.